Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 43

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 43
---
 realign salaries with market levels after considering individual responsibilities, performance and experience. In making decisions regarding salary increases, we may also draw upon the experience of our Board members with executives at other companies. The 2024 annual base salaries for our named executive officers are set forth in the table below.

| Name                      |     | 2024 Base Salary |
| Marshall Fordyce, M.D.(1) |     |         $620,000 |
| Jason Carter(2)           |     |         $470,000 |
| Robert Brenner, M.D.(3)   |     |         $480,000 |

| (1) | Dr. Fordyce’s base salary increased from $590,000 to $620,000 on February 16, 2024. |

| (2) | Mr. Carter joined us in November 2024. |

| (3) | Dr. Brenner joined us in January 2024. |

Cash Incentive Compensation In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash compensation designed to provide appropriate incentives to our executive officers to achieve pre-established annual corporate objectives and key results and to reward them for individual achievement towards these objectives and key results. The annual performance-based cash compensation each named executive officer is eligible to receive is generally based on the extent to which we achieve our corporate objectives and key results established by our Board each year. At the end of the year, our Compensation Committee reviews our performance against our corporate objectives and key results and approves, or recommends to our full Board that it approve, cash payouts based on achievement of our corporate objectives and key results, subject, in each case, to the named executive officer’s continued employment with us through the payment date of such amount. The Compensation Committee has generally considered each named executive officer’s individual contributions towards reaching our annual corporate objectives and key results but does not typically establish specific individual goals for our named executive officers. There is no minimum payout percentage or amount established for our named executive officers and, thus, the payment amounts vary from year to year based on corporate and individual performance, in each case pursuant to the terms of our named executive officer’s offer letter described below. For 2024, Dr. Fordyce’s, and Dr. Brenner’s target performance bonuses were 55% and 40%, respectively, of their respective base salaries. For 2024, annual cash incentives were based on the achievement of various clinical and operational metrics related to advancing the atacicept Ig